Replimune (REPL) shares dropped 19% after FDA rejected RP1 melanoma therapy for the second time, citing trial design issues. Stock halted twice.
Replimune (REPL) stock plunged 19% after FDA rejected RP1 melanoma drug for second time, citing inadequate clinical trial controls and design issues.
Replimune (REPL) stock plunged 19% after FDA rejected RP1 melanoma therapy for the second time, citing trial design flaws. Shares hit lowest level since Oct.
Michael Burry reveals purchases of Alibaba, JD.com, and GameStop shares while increasing put options on Nvidia and Palantir in his latest portfolio update.
Michael Burry discloses new stakes in Alibaba and JD.com while expanding bearish bets against Nvidia and Palantir through long-dated put options.
Finance
Replimune (REPL) shares dropped 19% after FDA rejected RP1 melanoma therapy for the second time, citing trial design issues. Stock halted twice.
Replimune (REPL) stock plunged 19% after FDA rejected RP1 melanoma drug for second time, citing inadequate clinical trial controls and design issues.
Replimune (REPL) stock plunged 19% after FDA rejected RP1 melanoma therapy for the second time, citing trial design flaws. Shares hit lowest level since Oct.
Michael Burry reveals purchases of Alibaba, JD.com, and GameStop shares while increasing put options on Nvidia and Palantir in his latest portfolio update.
Reviews
Inventory is a burden for almost all businesses, and for customized products, it is an even bigger hassle. Printful is…
Making Money
There are over one million websites that use Amazon affiliate links. If you want customers to pick your website over the other countless options in the…